⚡️Gold Bull Market Accelerates as Expert Targets $7,500 Amid Global Uncertainty https://ritzherald.com/gold-bull-market-accelerates-as-expert-targets-7500-amid-global-uncertainty/

TLSA Catalyst Ranking and Market Update: June 2025

https://www.tradingview.com/chart/TSLA/yo8HwHFI-TLSA-Catalyst-Ranking-and-Market-Update-June-2025/

Here's an updated/revised outlook for TSLA including all the primary
catalyst ranking and analyst ratings and overview of latest developments

🔋 1. EV Demand Growth
Strength: 9/10 → 9/10
Global electric vehicle adoption remains the dominant pillar. Tesla faces softer comp in Europe (–40.5% drop in May) wsj.com, but overall trend remains firmly upward. 🌍
🚗 2. Affordable Entry Level Model
Strength: 8.5/10 → 8.5/10
Tesla still on track to launch a < $25K EV in first half of 2025. Any delays or execution issues could pressure sentiment.
⚡️ 3. Battery Cost & Margin Improvement
Strength: 8/10 → 8/10
Margins saw slight relief Q1, driven by cost cuts f, but macro headwinds persist.

✅continue reading on TradingView

10 Small-Cap Biotechs with Key Catalysts for 2025 July List
https://www.tradingview.com/chart/IBB/12VGMavi-10-Small-Cap-Biotechs-with-Key-Catalysts-for-2025-July-List/
________________________________________
1. Allogene Therapeutics (NASDAQ: ALLO)
• Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission.
• Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates.
________________________________________
2. Lixte Biotechnology (NASDAQ: LIXT)
• Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025.
• Highlights: If efficacy signals emerge, could prompt partnerships or additional trials.

✅continue reading on TradingView